Kagawa university Miki, Kita District, Kagawa, Japan
Disclosure information not submitted.
Kanako Chujo1, Hiromi Shimada2, Hiroki Ozaki3, Risa Wakiya4, Shusaku Nakashima4, taichi miyagi5, Yusuke Ushio6, Koichi Sugihara7, Mao Mizusaki4, Rina Mino8, Ryoko Kagawa9, Hayamasa Yamaguchi9, Tomohiro Kameda2 and Hiroaki Dobashi2, 1Kagawa University, Miki, Kita District, Kagawa, Japan, 2Kagawa University, Kagawa, Japan, 3Department of Rheumatology, KKR Takamatsu Hospital, Kagawa, Japan, 4Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 5Kagawa university, Kidagun, Japan, 6Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, 7Kagawa University, Miki-cho, Kita-gun, Japan, 8Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 9Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Most patients with IgG4-related disease (IgG4-RD) have a good response to glucocorticoid (GC) therapy, however, disease relapses sometimes occur during GC tapering. Therefore, the immunosuppressants are considered in these cases. On the other hand, the predictors of disease relapse and the efficacy of immunosuppressants have not been fully clarified.
Therefore, we retrospectively analyzed the current treatment status of patients with IgG4-RD to identify the efficacy of immunosuppressants for disease relapse.
Methods: We used the data of patients with IgG4-RD diagnosed by May 2023 based on the 2020 revised comprehensive diagnostic criteria for IgG4-RD, and extracted those who had undergone therapeutic intervention. We retrospectively evaluated the organ involved, immunological findings including serum IgG4 levels, treatment agents, especially in GC dose and concomitant use of immunosuppressants, and the presence of relapse within 2 years after the start of treatment.
Results: 95 patients were diagnosed according to the 2020 revised comprehensive diagnostic criteria for IgG4-RD. Of these, 59 patients underwent therapeutic intervention, and all cases were initially treated with GC at a mean dose of 0.54 mg/kg body weight. Immunosuppressants were used concomitantly in 30 patients (50.8%), mostly azathioprine. In 17 of these cases, immunosuppressants were started either at the time of initial therapy or GC dose reduction. There was no significant difference between the 17 patients who received these immunosuppressants and the other patients (Table 1), however, the rate of definite cases tended to be higher in the cases who received immunosuppressants (P=0.06). 15 patients (25.4%) relapsed during GC reduction, and the mean time to disease relapse from the start of treatment was 33.2±32.0 months. Most of the disease relapsed cases were treated with GC monotherapy, and after relapse, immunosuppressants were administered in addition to increased doses of GC. Additionally, 39 patients who continued treatment for 2 years were analyzed separately according to whether they relapsed or not (Table 2). There were no significant differences in age at diagnosis, gender, number of lesions, immunological findings including serum IgG4 levels, or GC dose at the start of treatment. However, all patients who had received immunosuppressants either at the time of initial treatment or GC dose reduction did not relapse during the 2-year period (Figure). Their GC dose at 2 years after the start of treatment was 4.1 ± 2.1 mg/day. In contrast, the GC dose at relapse in the 6 patients relapsing within 2 years was 7.8 ± 1.4 mg/day.
Conclusion: No relapses were observed in patients treated with immunosuppressants during the first 2 years of treatment. Early concomitant use of immunosuppressants is a useful therapeutic strategy for IgG4-RD, but further studies are needed to determine which patients should be considered for concomitant use.
K. Chujo: None; H. Shimada: None; H. Ozaki: None; R. Wakiya: None; S. Nakashima: None; t. miyagi: None; Y. Ushio: None; K. Sugihara: None; M. Mizusaki: None; R. Mino: None; R. Kagawa: None; H. Yamaguchi: None; T. Kameda: None; H. Dobashi: None.
